A Randomized, Double-Blind, Placebo-Controlled Clinical Trial on Once-Daily Atomoxetine Hydrochloride in Taiwanese Children and Adolescents with Attention-Deficit/Hyperactivity Disorder
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The aim of this study was to assess the efficacy and safety of the once-daily atomoxetine compared with placebo in pediatric patients with attention-deficit/hyperactivity disorder (ADHD) in Taiwan. METHOD: The study sample included 106 patients aged 6-16 years who met the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) criteria of ADHD randomly assigned to atomoxetine once daily (n = 72) and placebo once daily (n = 34) in a double-blind, 6-week treatment study. The primary efficacy measure was the total score of the ADHD Rating Scale-IV Parents Version: Investigator Administered and Scored. The secondary efficacy measures included the Clinical Global Impressions--ADHD--Severity and Chinese Conner's Parent and Teacher Rating Scale--Revised: Short Form. Data were analyzed on an intent-to-treat basis and a last-observation-carried-forward approach. RESULTS: The two treatment groups did not differ in demographics and baseline measures. Compared to the placebo group, the atomoxetine group showed significantly greater reductions in ADHD-related symptoms according to the ratings of investigators, parents, and teachers. The treatment effect size of the primary efficacy measure was 0.70 at the end of study. Adverse events reported significantly more frequently with atomoxetine were decreased appetite (36.1%) and nausea (16.6%). No drug-related serious adverse event was observed. CONCLUSIONS: Once-daily atomoxetine is an effective, well-tolerable, and safe treatment for children and adolescents with ADHD in Taiwan.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.12.1073 · Cited by 3,372
Conners, C. K., Sitarenios, G., Parker, J. D. A., & Epstein, J. N. (1998) · Journal of Abnormal Child Psychology · doi:10.1023/a:1022602400621 · Cited by 1,772
Diagnosis and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents
Goldman, L. S. (1998) · JAMA · doi:10.1001/jama.279.14.1100 · Cited by 1,082
Pharmacotherapy of Attention-Deficit Hyperactivity Disorder across the Life Cycle
SPENCER, T., BIEDERMAN, J., WILENS, T., HARDING, M., O'DONNELL, D., & GRIFFIN, S. (1996) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199604000-00008 · Cited by 830
Conners, C. K., Sitarenios, G., Parker, J. D. A., & Epstein, J. N. (1998) · Journal of Abnormal Child Psychology · doi:10.1023/a:1022606501530 · Cited by 678
Michelson, D., Faries, D., Wernicke, J., Kelsey, D., Kendrick, K., Sallee, F. R., Spencer, T., & the Atomoxetine ADHD Study Group (2001) · Pediatrics · doi:10.1542/peds.108.5.e83 · Cited by 666
Michelson, D., Allen, A. J., Busner, J., Casat, C., Dunn, D., Kratochvil, C., Newcorn, J., Sallee, F. R., Sangal, R. B., Saylor, K., et al. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.11.1896 · Cited by 599 · cited 15×
“This early onset of treatment efficacy has been observed in other studies (Biederman et al. 2002; Michelson et al. 2002; Kaplan et al. 2004; Kelsey et al. 2004), which indicated a good clinical lead-in response for atomoxetine in the early stage of treatment.”
InfluentialSelf-citationMTA Cooperative Group (2004) · Pediatrics · doi:10.1542/peds.113.4.754 · Cited by 589
Kelsey, D. K., Sumner, C. R., Casat, C. D., Coury, D. L., Quintana, H., Saylor, K. E., Sutton, V. K., Gonzales, J., Malcolm, S. K., Schuh, K. J., et al. (2004) · Pediatrics · doi:10.1542/peds.114.1.e1 · Cited by 464 · cited 13×
“This early onset of treatment efficacy has been observed in other studies (Biederman et al. 2002; Michelson et al. 2002; Kaplan et al. 2004; Kelsey et al. 2004), which indicated a good clinical lead-in response for atomoxetine in the early stage of treatment.”
InfluentialSelf-citationSpencer, T., Heiligenstein, J. H., Biederman, J., Faries, D. E., Kratochvil, C. J., Conners, C. K., & Potter, W. Z. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1209 · Cited by 333 · cited 8×
“…discontinuation due to adverse events were less than 5% (Michelson et al. 2001; Spencer et al. 2001; Biederman et al. 2002; Michelson et al. 2002; Spencer et al. 2002; Buitelaar et al. 2004; Kelsey et al. 2004), indicating that atomoxetine is safe and well-tolerated in children and adolescents…”
BackgroundResultInfluential
Cited by
Garnock-Jones, K. P., & Keating, G. M. (2009) · Pediatric Drugs · doi:10.2165/00148581-200911030-00005 · Cited by 392
Schwartz, S., & Correll, C. U. (2014) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2013.11.005 · Cited by 166
Reed, V. A., Buitelaar, J. K., Anand, E., Day, K. A., Treuer, T., Upadhyaya, H. P., Coghill, D. R., Kryzhanovskaya, L. A., & Savill, N. C. (2016) · CNS Drugs · doi:10.1007/s40263-016-0349-0 · Cited by 113
Gau, S. S.-F., & Chiang, H.-L. (2009) · Sleep · doi:10.1093/sleep/32.5.671 · Cited by 100
Self-citationGau, S. S.-F., & Shang, C.-Y. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709990836 · Cited by 91
“No significant change of body weight and vital signs from baseline to follow-up as demonstrated in this study and in a randomized, double-blind, placebo-controlled study in Taiwan (Gau et al. 2007b) suggests that atomoxetine may be safe and well tolerated in Taiwanese children.”
BackgroundMethodResultInfluentialSelf-citation
Metadata
- Authors
- Gau, S. S. F., Huang, Y.-S., Soong, W.-T., Chou, M.-C., Chou, W.-J., Shang, C.-Y., Tseng, W.-L., Allen, A. J., & Lee, P.
- Venue
- Journal of Child and Adolescent Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2007-08
- Volume
- 17
- Issue
- 4
- Pages
- 447-460
- ISSN
- 1044-5463 (ISSN-L)
- 1557-8992
- OpenAlex
- W2088606503
- Cited by
- 65
- References
- 15
- FWCI
- 3.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial on Once-Daily Atomoxetine Hydrochloride in Taiwanese Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. https://app.cochat.ai/papers/10.1089/cap.2006.0091
- The paper
- Gau, S. S. F., Huang, Y.-S., Soong, W.-T., Chou, M.-C., Chou, W.-J., Shang, C.-Y., Tseng, W.-L., Allen, A. J., & Lee, P. (2007). A Randomized, Double-Blind, Placebo-Controlled Clinical Trial on Once-Daily Atomoxetine Hydrochloride in Taiwanese Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. Journal of Child and Adolescent Psychopharmacology. https://doi.org/10.1089/cap.2006.0091
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.